Physician
Robeson Pediatrics, P.A.
Robeson Pediatrics, P.A. was paid $8.59M by Medicaid between Jan 2018 and Dec 2024, across 65 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 26% of everything it billed.
33Billing provider infoROBESON PEDIATRICS, P.A.
LUMBERTON, NC 28358
LUMBERTON, NC 28358
33aNPI1497071526assigned 04/14/2010
33bProvider typePediatric Adolescent Medicine Physician
28Total paid$8.59M
24GClaims488,660
24DCodes billed65
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatric Adolescent Medicine Physician providers in North Carolina
Rank by total paid#6 of 20
Median peer was paid$4.16M
This provider vs. median2.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 32,694 | $877K | |
| 2019 | 33,068 | $920K | |
| 2020 | 32,006 | $858K | |
| 2021 | 75,269 | $1.19M | |
| 2022 | 116,232 | $1.75M | |
| 2023 | 107,334 | $1.75M | |
| 2024incomplete | 92,057 | $1.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 26% | 28,652 | 23,692 | $2.25M |
| 99199 | Unlisted special service, procedure or report | 15% | 207,774 | 107,356 | $1.32M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 12% | 18,199 | 15,405 | $1.00M |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.5% | 7,408 | 6,115 | $559K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 6.4% | 15,201 | 12,857 | $549K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 6.0% | 6,977 | 6,049 | $513K |
| 99401 | 4.2% | 13,902 | 9,109 | $360K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.8% | 4,445 | 3,585 | $323K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 3.6% | 8,852 | 7,237 | $307K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.3% | 23,679 | 19,779 | $287K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.8% | 7,377 | 5,548 | $156K |
| D0145 | Oral evaluation for a patient under three years of age | 1.8% | 4,921 | 4,348 | $155K |
53 more codes
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.8% | 1,883 | $154K |
| 92587 | 1.3% | 13,223 | $111K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.1% | 11,610 | $91K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.0% | 10,502 | $90K |
| 99051 | <1% | 3,569 | $72K | |
| D1206 | Topical application of fluoride varnish | <1% | 4,941 | $68K |
| 96127 | <1% | 12,495 | $62K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,514 | $49K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 1,233 | $21K |
| 81003 | <1% | 12,932 | $20K | |
| 90461 | <1% | 6,218 | $11K | |
| 83655 | <1% | 823 | $10K | |
| 0072A | <1% | 184 | $9K | |
| 0071A | <1% | 166 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 457 | $6K |
| 96161 | <1% | 1,891 | $6K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 44 | $5K |
| 99173 | <1% | 8,933 | $5K | |
| 86756 | <1% | 358 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 333 | $3K |
| 90651 | <1% | 532 | $3K | |
| 80061 | Lipid panel | <1% | 145 | $2K |
| 90686 | <1% | 4,367 | $1K | |
| 99177 | <1% | 4,472 | $1K | |
| 90670 | <1% | 2,633 | $697.14 | |
| 90734 | <1% | 208 | $690.21 | |
| G9919 | Screening performed and positive and provision of recommendations | <1% | 17 | $433.20 |
| 36415 | Collection of venous blood by venipuncture | <1% | 190 | $414.93 |
| 94760 | <1% | 6,088 | $336.66 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 80 | $226.17 |
| 36416 | <1% | 12,611 | $123.73 | |
| 90633 | <1% | 1,108 | $97.39 | |
| 90647 | <1% | 1,577 | $57.92 | |
| 90715 | <1% | 46 | $48.18 | |
| 90672 | <1% | 83 | $24.82 | |
| 90656 | <1% | 299 | $19.55 | |
| 92551 | <1% | 46 | $11.02 | |
| 99000 | <1% | 5,210 | $1.36 | |
| 90680 | 0% | 1,226 | $0.00 | |
| 3008F | 0% | 3,365 | $0.00 | |
| 90723 | 0% | 1,515 | $0.00 | |
| J7609 | Albuterol, inhalation solution, compounded product, administered through dme, unit dose, 1 mg | 0% | 275 | $0.00 |
| 90716 | 0% | 126 | $0.00 | |
| 90677 | 0% | 94 | $0.00 | |
| 91307 | 0% | 404 | $0.00 | |
| 90696 | 0% | 180 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 26 | $0.00 |
| 90660 | 0% | 18 | $0.00 | |
| 90710 | 0% | 208 | $0.00 | |
| 90700 | 0% | 123 | $0.00 | |
| 91300 | 0% | 51 | $0.00 | |
| 90707 | 0% | 126 | $0.00 | |
| 90685 | 0% | 515 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLOWRY, KATIE (PRESIDENT)